Ginseng Bioactive Components as Gut-Brain Axis Modulators: Therapeutic Potential in Multifactorial Diseases
Narrative review maps mechanisms by which ginseng ginsenosides, polysaccharides, and polyphenols act on the gut-brain axis in preclinical models.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The abstract reports that ginseng components modulate the gut-brain axis through gut microbiota alteration, intestinal barrier protection, anti-inflammatory action, and neurotransmitter regulation. Preclinical potential is described for neurodegenerative diseases, mood disorders, and metabolic diseases. No original primary data are presented.
How it was done
Systematic literature review searching major databases for studies on gut-brain axis regulation by ginseng bioactive components. Exact selection methods and inclusion criteria are not detailed in the abstract.
Risk of bias
This is a narrative/systematic review without quantitative meta-analysis; described effects are predominantly preclinical. Absence of robust human data precludes any direct clinical inference.
What this study does NOT prove
This review does not prove clinical efficacy of ginseng for any disease mediated through the gut-brain axis in humans.
In clinical practice
There is insufficient evidence to recommend ginseng as a clinical intervention based on this review. Preclinical findings justify controlled clinical trials, not immediate application.
Limitations
This is a narrative/systematic review without quantitative meta-analysis; described effects are predominantly preclinical. Absence of robust human data precludes any direct clinical inference.
Technical appendix
Version history
- 1.0 · 2026-08-31 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.